Arecor Therapeutics PLC (AREC) - Total Liabilities

Latest as of December 2025: GBX1.65 Million GBX ≈ $200.39 USD

Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has total liabilities worth GBX1.65 Million GBX (≈ $200.39 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Arecor Therapeutics PLC equity growth rate to track the company's year-over-year net asset growth rate.

Arecor Therapeutics PLC - Total Liabilities Trend (2017–2025)

This chart illustrates how Arecor Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data.

Arecor Therapeutics PLC Competitors by Total Liabilities

The table below lists competitors of Arecor Therapeutics PLC ranked by their total liabilities.

Company	Country	Total Liabilities
M Winkworth PLC LSE:WINK	UK	GBX1.83 Million
Sejahtera Bintang Abadi Textile Tbk JK:SBAT	Indonesia	Rp495.54 Billion
Global Gas Corporation NASDAQ:HGAS	USA	$322.75K
SMG EUROPEAN RECOV. EO 1 F:RCVR	Germany	€16.44 Million
PCI Biotech Holding ASA OL:PCIB	Norway	Nkr6.01 Million
Jpmorgan Global Core Real Assets Ltd LSE:JARA	UK	GBX282.00K
Virpax Pharmaceuticals Inc NASDAQ:VRPX	USA	$2.47 Million
ImmuPharma PLC LSE:IMM	UK	GBX1.24 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Arecor Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AREC market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.35	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Arecor Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Arecor Therapeutics PLC (2017–2025)

The table below shows the annual total liabilities of Arecor Therapeutics PLC from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	GBX1.65 Million ≈ $200.39	-51.17%
2024-12-31	GBX3.37 Million ≈ $410.40	-42.34%
2023-12-31	GBX5.85 Million ≈ $711.78	+35.73%
2022-12-31	GBX4.31 Million ≈ $524.40	+81.70%
2021-12-31	GBX2.37 Million ≈ $288.60	-32.42%
2020-12-31	GBX3.51 Million ≈ $427.07	+219.76%
2019-12-31	GBX1.10 Million ≈ $133.56	-11.12%
2019-05-31	GBX1.23 Million ≈ $150.26	-11.56%
2018-05-31	GBX1.40 Million ≈ $169.90	+13.33%
2017-05-31	GBX1.23 Million ≈ $149.92	--

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$275.63K

GBX2.27 Billion GBX

Market Cap Rank

#31116 Global

#992 in UK

Share Price

GBX60.00

Change (1 day)

-1.64%

52-Week Range

GBX59.00 - GBX92.50

All Time High

GBX450.00